Sickle Cell Drug

EU Regulators Call for Withdrawal of Authorization for Novartis’ Sickle Cell Drug Adakveo Following Phase 3 Setback

After the phase 3 trial of Novartis’ sickle cell disease drug, Adakveo, yielded disappointing results, regulators in Europe have revisited ...